Novartis Oncology Turkey and Eczacıbaşı İlaç Pazarlama A.Ş. Sign Cooperation Agreement

Turkchem 26 Nov 2019 74 2 dk okuma

TURKCHEM

Novartis Oncology Turkey and Eczacıbaşı İlaç Pazarlama A.Ş. Sign Cooperation Contract

Novartis Oncology Turkey and Eczacıbaşı İlaç Pazarlama A.Ş., which operates in hospital products, dermatology, urology, gastroenterology, pediatrics, consumer health and oncology with 350 employees, have signed a joint cooperation contract that places patient needs and operational efficiency at its core. Under the framework of the contract, Novartis Oncology Turkey has granted sales, promotion and distribution rights for Acromegaly, NET, GIST, KML and three products in the Lung Cancer treatment area (while retaining their licenses with Novartis) in Turkey and the TRNC to Eczacıbaşı İlaç Pazarlama A.Ş. for a limited period as of 1 August 2019. Pınar Üstündağ, General Manager of Novartis Oncology Turkey, stated: "As Novartis Oncology, we continue to develop and deliver innovative oncology medicines to meet the medical needs of patients with cancer and related diseases.

Within this framework, we have one of the largest global portfolios with over 20 products for more than 25 diseases in the field of oncology, hematology and rare diseases.

In line with the ever-increasing development and value-added needs in the pharmaceutical sector, we view our responsibility in this area through support for cooperation, employment, national economy and R&D capacity for targeted improvements in public health." Canan Bademlioğlu, General Director of Eczacıbaşı İlaç Pazarlama A.Ş., stated: "For more than 70 years, we have been strengthening our patient-oriented approach through partnerships with leading organizations around the world and contributing to proper patient treatment in our country. This important agreement with Novartis Oncology reinforces our belief in such cooperation, aligning with our long-standing history, our responsibility to patients and society, and our corporate vision. For this reason, we view our strategic cooperation as one of the important milestones in our goal of contributing to oncology patient treatment based on their needs."